Amgen Positions Ivabradine As A Foot In The Door Ahead Of PCSK9 Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen executives laid out the case for the heart failure candidate ivabradine, which will serve as a foundation for the launch of the company’s highly anticipated PCSK9 inhibitor, during a presentation at AHA. The company also presented the first 52-week data on evolocumab.